Accendra Health, Inc.

NYSE:ACH

Medical - Distribution

Healthcare
$0.71 +3.64%

+$0.12 today

Market cap
$54.22M
Beta
1.63
P/E (TTM)
-0.2
EPS (TTM)
-$14.11
52W Low $1.84High $9.55

Volume 1.41M

Average 0.83M

ACH Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Accendra Health, Inc.NYSE: ACH

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns negative

Q1 FY2026 accounts receivables was -$7.8M, compared with $111.61M a year earlier. Trailing-twelve-month accounts receivables was $2.95M. Over 3 fiscal years it compounded at +380.8% a year.

Context

  • Accounts receivables amounted to 4.4% of revenue in FY2025, up 3.5 pp from a year earlier.
  • Accounts receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly accounts receivables holds near -$7.8M or moves back toward the trailing-twelve-month quarterly average of $738.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$7.8M-171.8% QoQ
Last fiscal yearDec 2025
$122.36M+229.4% YoY
LTMMar 2026
$2.95M-96.7% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-107.0%——
1 year+229.4%——
3-year CAGR+380.8%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
122.36M USD
Year-over-year change
+229.4%

Accounts Receivables vs competitors

How ACH compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -96.7% is the 7th highest of 9, against a peer median of +310.6%.
  • Accounts receivables amounts to 0.1% of revenue for ACH, versus a peer median of 4.4%.
ACH Competitors
Accounts Receivables for ACH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGCCanopy Growth CorporationLTM Mar 2026CA$23.54M CAD+624.8%+60.2%7.5%
OMOutset Medical, Inc.LTM Mar 2026$8.65M USD+7764.5%—7.4%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$6.81M USD+5438.2%+253.5%81.4%
HITIHigh Tide Inc.LTM Apr 2026CA$5.01M CAD-470.6%-28.9%0.7%
ACHAccendra Health, Inc.LTM Mar 2026$2.95M USD-96.7%+380.8%0.1%
EDITEditas Medicine, Inc.LTM Mar 2026$2.08M USD+685.7%—5.4%
SGHTSight Sciences, Inc.LTM Mar 2026$1.14M USD-118.2%—1.4%
BIOABioAge Labs, Inc.LTM Mar 2026$348K USD-3.6%—3.4%
CVRXCVRx, Inc.LTM Mar 2026$92K USD-82.2%-22.0%0.2%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$0 USD———
CABACabaletta Bio, Inc.LTM Mar 2026$0 USD———
Peer median (excluding ACH) —+310.6%+19.1%4.4%

Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income221.59M22.39M(41.3M)(362.69M)(102.68M)
Depreciation & Amortization90.62M228.67M287.38M264.78M214.52M
Deferred Income Tax(29.74M)(26.36M)(23.65M)(26.12M)(17.89M)
Stock-Based Compensation25.02M20.99M23.22M26.84M12.87M
Change in Working Capital(261.4M)89.77M522.29M(25.44M)65.21M
Accounts Receivables(2.2M)1.1M166.58M(94.55M)122.36M
Inventory(263.44M)166.56M224.34M(26.23M)(6.85M)
Accounts Payables3.55M13.65M31M65.19M6.48M
Other Working Capital692K(91.54M)100.37M30.15M(56.78M)
Other Non-Cash Items78.09M(10.45M)(27.22M)284.12M(273.83M)
Operating Cash Flow124.18M325.01M740.71M161.5M(101.79M)
Capital Expenditures(49.69M)(166.58M)(207.89M)(228.16M)(201.33M)
Acquisitions (Net)(43.37M)(1.68B)00324.26M
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities39.43M46.71M53.62M94.33M11.12M
Investing Cash Flow(53.63M)(1.8B)(137.25M)(116.53M)144.42M
Debt Repayment(95.35M)1.58B(416.69M)(244.2M)203.5M
Common Stock Issued00000
Common Stock Repurchased0000(10.18M)
Dividends Paid(731K)0000
Other Financing Activities(33.4M)(85.4M)(637K)(23.41M)(5.24M)
Financing Cash Flow(129.48M)1.5B(417.33M)(267.6M)188.08M
Effect of Forex Changes(3.54M)(3.49M)613K(901K)1.9M
Net Change in Cash(62.47M)14.15M186.74M(223.54M)232.61M
Free Cash Flow74.49M158.42M532.82M(66.67M)(303.12M)

Accendra Health, Inc.

NYSE:ACH

Intrinsic Alpha fair value

Locked

Current Price

$0.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.